GSK癌症药物研发回归见效:六款获批药物及新适应症进展
STAT+: GSK sees its return to cancer start to pay off
GSK六款获批癌症药物近期取得新适应症进展,其靶向B7-H4的药物在ESMO展示首个全球研究数据,并宣布预计数周内将获批新肺癌药物。十年前退出癌症领域后,GSK通过持续研发实现业务复苏。
The company could soon have its sixth approved cancer drug
![]()
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
MADRID — In the past week, a GSK cancer drug picked up an approval for another tumor type, the company unveiled the first data from a global study of a promising next-generation chemotherapy, and a medicine that the firm has licensed got the limelight in a presidential session at a major oncology conference here.
GSK is also awaiting another expected approval in the coming weeks, this time for a new lung cancer drug.
It’s a good run considering GSK was out of oncology a decade ago.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
Europe Correspondent
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
来源:STAT 主站 · statnews.com